Literature DB >> 28205360

Advanced serious illness, multimorbidity, and multibeneficence: The role of communication.

Jeffrey Cohn1.   

Abstract

Sturmberg et al write about multimorbidity as "several diagnosable diseases within the same individual." They posit that this syndrome is the result of multiple interconnected disturbances reflecting scale-free, fractal signs of pathology ranging from biochemical/hormonal alterations at one end of a spectrum to community and societal ills at the other. In this commentary, I will be focusing on 3 perspectives: 1) a preterminal phase of multimorbidity that is indicative of that loss of reparative or even homeokinetic properties, known by some as "advanced serious illness"; 2) the manifestations of advanced serious illness multimorbidity that, using the same networks that connect into the patient, are signs of this syndrome at the levels of the immediate family/friend social network, the broader community, and society at large; and 3) the potential for these same networks that transmit pathological forces to convey the positive effects of therapeutic interventions in a scale-free manner, with a focus on how conversation can lead to what I'm calling "multibeneficence."
© 2017 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28205360     DOI: 10.1111/jep.12706

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  2 in total

1.  An alternate level of care plan: Co-designing components of an intervention with patients, caregivers and providers to address delayed hospital discharge challenges.

Authors:  Kerry Kuluski; Julia W Ho; Lauren Cadel; Sara Shearkhani; Charissa Levy; Michelle Marcinow; Allie Peckham; Jane Sandercock; Donald J Willison; Sara Jt Guilcher
Journal:  Health Expect       Date:  2020-06-30       Impact factor: 3.377

2.  Transitional care from skilled nursing facilities to home: study protocol for a stepped wedge cluster randomized trial.

Authors:  M Toles; C Colón-Emeric; L C Hanson; M Naylor; M Weinberger; J Covington; J S Preisser
Journal:  Trials       Date:  2021-02-05       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.